JP7712913B2 - 心血管リスク／イベントの予測及びその使用 - Google Patents

心血管リスク／イベントの予測及びその使用

Info

Publication number
JP7712913B2
JP7712913B2 JP2022513923A JP2022513923A JP7712913B2 JP 7712913 B2 JP7712913 B2 JP 7712913B2 JP 2022513923 A JP2022513923 A JP 2022513923A JP 2022513923 A JP2022513923 A JP 2022513923A JP 7712913 B2 JP7712913 B2 JP 7712913B2
Authority
JP
Japan
Prior art keywords
subject
risk
biomarker
event
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022513923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546515A (ja
JPWO2021046074A5 (https=
JP2022546515A5 (https=
Inventor
マイケル ヒンターベルグ
ガーギ ダッタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Inc
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of JP2022546515A publication Critical patent/JP2022546515A/ja
Publication of JPWO2021046074A5 publication Critical patent/JPWO2021046074A5/ja
Publication of JP2022546515A5 publication Critical patent/JP2022546515A5/ja
Priority to JP2025073876A priority Critical patent/JP2025118715A/ja
Application granted granted Critical
Publication of JP7712913B2 publication Critical patent/JP7712913B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
JP2022513923A 2019-09-03 2020-09-02 心血管リスク／イベントの予測及びその使用 Active JP7712913B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025073876A JP2025118715A (ja) 2019-09-03 2025-04-28 心血管リスク／イベントの予測及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962895383P 2019-09-03 2019-09-03
US62/895,383 2019-09-03
PCT/US2020/048981 WO2021046074A1 (en) 2019-09-03 2020-09-02 Cardiovascular risk event prediction and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025073876A Division JP2025118715A (ja) 2019-09-03 2025-04-28 心血管リスク／イベントの予測及びその使用

Publications (4)

Publication Number Publication Date
JP2022546515A JP2022546515A (ja) 2022-11-04
JPWO2021046074A5 JPWO2021046074A5 (https=) 2023-08-28
JP2022546515A5 JP2022546515A5 (https=) 2023-08-28
JP7712913B2 true JP7712913B2 (ja) 2025-07-24

Family

ID=72521733

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513923A Active JP7712913B2 (ja) 2019-09-03 2020-09-02 心血管リスク／イベントの予測及びその使用
JP2025073876A Pending JP2025118715A (ja) 2019-09-03 2025-04-28 心血管リスク／イベントの予測及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025073876A Pending JP2025118715A (ja) 2019-09-03 2025-04-28 心血管リスク／イベントの予測及びその使用

Country Status (11)

Country Link
US (1) US20220349904A1 (https=)
EP (1) EP4025916A1 (https=)
JP (2) JP7712913B2 (https=)
KR (1) KR20220057534A (https=)
CN (1) CN114641692B (https=)
AU (1) AU2020343243A1 (https=)
BR (1) BR112022003666A2 (https=)
CA (1) CA3151482A1 (https=)
IL (1) IL290951A (https=)
MX (1) MX2022002314A (https=)
WO (1) WO2021046074A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025173327A1 (ja) * 2024-02-14 2025-08-21 Ｎｅｃソリューションイノベータ株式会社 罹患死亡可能性予測モデル、罹患死亡可能性予測方法、罹患死亡可能性予測装置、プログラム、及び記録媒体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056034A1 (en) 2006-11-10 2008-05-15 Hytest Ltd. Stable standards for bnp immunoassays
JP2016527519A (ja) 2013-08-09 2016-09-08 イノトレム 心血管疾患または心血管イベントを有するリスクを予測するための方法およびキット
JP2017530356A (ja) 2014-09-26 2017-10-12 ソマロジック, インコーポレイテッドSomaLogic, Inc. 心血管系のリスクイベントの予測及びその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
DK2172566T4 (da) 2007-07-17 2022-06-13 Somalogic Inc Fremgangsmåde til generering af aptamerer med forbedrede off-rates
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
KR20120101064A (ko) * 2009-11-13 2012-09-12 비쥐 메디신, 인코포레이티드 심근 경색의 위험 인자 및 예측
EP2593566B1 (en) * 2010-07-14 2018-01-24 The Regents of The University of California Biomarkers for diagnosis of transient ischemic attacks
CN103429753A (zh) 2010-09-27 2013-12-04 私募蛋白质体公司 间皮瘤生物标记及其用途
MX373248B (es) * 2011-09-30 2020-05-11 Somalogic Operating Co Inc Prediccion de riesgo de evento cardiovascular y usos del mismo.
CN108291330A (zh) * 2015-07-10 2018-07-17 西弗吉尼亚大学 卒中和卒中严重性的标志物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056034A1 (en) 2006-11-10 2008-05-15 Hytest Ltd. Stable standards for bnp immunoassays
JP2016527519A (ja) 2013-08-09 2016-09-08 イノトレム 心血管疾患または心血管イベントを有するリスクを予測するための方法およびキット
JP2017530356A (ja) 2014-09-26 2017-10-12 ソマロジック, インコーポレイテッドSomaLogic, Inc. 心血管系のリスクイベントの予測及びその使用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Endothelium-derived extracellular vesicles promote splenic monocyte mobilization in myocardial infarction，JCI Insight，2017年09月07日，Vol.2, No.17, e93344，<DOI: 10.1172/jci.insight.93344>
FEI, X., et al.，Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer，BioMed research international，2017年，2017:8983763，pp.1-8，<Epub 2017 Jan 26>, <DOI: 10.1155/2017/8983763>
GANZ, P., et al.，Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease，The Journal of American Medical Association，2016年06月21日，Vol.315, No.23，pp.2532-2541，<DOI: 10.1001/jama.2016.5951>
KNEIHSL, M., et al.，Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke，Stroke，2019年08月，Vol.50, No.8，pp.2223-2226，<DOI: 10.1161/STROKEAHA.119.025339>
VIVIANO, A., et al.，Proteomics of the epicardial fat secretome and its role in post-operative atrial fibrillation，Europace，2018年07月01日，Vol.20, No.7，<DOI: 10.1093/europace/eux113>
WAN, G., et al.，Screening genes associated with elevated neutrophil-to-lymphocyte ratio in chronic heart failure，Molecular medicine reports，2018年08月，Vol.18, No.2，pp.1415-1422，<DOI:10.3892/mmr.2018.9132>
WANG, Y,K., et al.，Prognostic Utility of Soluble TREM-1 in Predicting Mortality and Cardiovascular Events in Patients With Acute Myocardial Infarction，Journal of the American Heart Association，2018年06月09日，Vol.7, No.12, e008985，pp.1-11，<DOI: 10.1161/JAHA.118.008985>

Also Published As

Publication number Publication date
JP2025118715A (ja) 2025-08-13
JP2022546515A (ja) 2022-11-04
CN114641692A (zh) 2022-06-17
US20220349904A1 (en) 2022-11-03
CN114641692B (zh) 2025-09-16
MX2022002314A (es) 2022-06-02
AU2020343243A1 (en) 2022-03-10
CA3151482A1 (en) 2021-03-11
IL290951A (en) 2022-04-01
WO2021046074A1 (en) 2021-03-11
EP4025916A1 (en) 2022-07-13
KR20220057534A (ko) 2022-05-09
BR112022003666A2 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
JP7270696B2 (ja) 心血管系のリスクイベントの予測及びその使用
CN116008563B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
JP2026021411A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用
JP2025118715A (ja) 心血管リスク／イベントの予測及びその使用
JP7792338B2 (ja) 耐糖能異常障害を決定する方法
US20230393146A1 (en) Cardiovascular Event Risk Prediction
HK40078070B (zh) 心血管风险事件预测及其用途
HK40095601A (zh) 心血管事件风险预测
JP2024525146A (ja) 腎不全の予測及びその使用
JP2025516097A (ja) 試料品質評価の方法
HK40078070A (zh) 心血管风险事件预测及其用途
HK40078108A (en) Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK40074269A (en) Methods of determining impaired glucose tolerance
HK1259917A1 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250711

R150 Certificate of patent or registration of utility model

Ref document number: 7712913

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150